A portal vein injection model to study liver metastasis of breast cancer

Erica T. Goddard, Jacob Fischer, Pepper Schedin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30% of cases with breast cancer metastasis, and results in poor outcomes with median survival rates of only 4.8 - 15 months. Current rodent models of breast cancer metastasis, including primary tumor cell xenograft and spontaneous tumor models, rarely metastasize to the liver. Intracardiac and intrasplenic injection models do result in liver metastases, however these models can be confounded by concomitant secondary-site metastasis, or by compromised immunity due to removal of the spleen to avoid tumor growth at the injection site. To address the need for improved liver metastasis models, a murine portal vein injection method that delivers tumor cells firstly and directly to the liver was developed. This model delivers tumor cells to the liver without complications of concurrent metastases in other organs or removal of the spleen. The optimized portal vein protocol employs small injection volumes of 5 - 10 μl, ≥ 32 gauge needles, and hemostatic gauze at the injection site to control for blood loss. The portal vein injection approach in Balb/c female mice using three syngeneic mammary tumor lines of varying metastatic potential was tested; high-metastatic 4T1 cells, moderate-metastatic D2A1 cells, and low-metastatic D2.OR cells. Concentrations of ≤ 10,000 cells/injection results in a latency of ~ 20 - 40 days for development of liver metastases with the higher metastatic 4T1 and D2A1 lines, and > 55 days for the less aggressive D2.OR line. This model represents an important tool to study breast cancer metastasis to the liver, and may be applicable to other cancers that frequently metastasize to the liver including colorectal and pancreatic adenocarcinomas.

Original languageEnglish (US)
Article numbere54903
Pages (from-to)1-10
Number of pages10
JournalJournal of Visualized Experiments
Volume2016
Issue number118
DOIs
StatePublished - Dec 26 2016

Fingerprint

Portal Vein
Liver
Breast Neoplasms
Neoplasm Metastasis
Injections
Tumors
Cells
Neoplasms
Spleen
Hemostatics
Heterografts
Needles
Gages
Immunity
Rodentia
Adenocarcinoma
Blood
Survival Rate
Mortality
Growth

Keywords

  • Breast cancer
  • Cancer research
  • Intraportal injection
  • Issue 118
  • Liver metastasis
  • Mouse model
  • Portal vein
  • Survival surgery

ASJC Scopus subject areas

  • Neuroscience(all)
  • Chemical Engineering(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A portal vein injection model to study liver metastasis of breast cancer. / Goddard, Erica T.; Fischer, Jacob; Schedin, Pepper.

In: Journal of Visualized Experiments, Vol. 2016, No. 118, e54903, 26.12.2016, p. 1-10.

Research output: Contribution to journalArticle

Goddard, Erica T. ; Fischer, Jacob ; Schedin, Pepper. / A portal vein injection model to study liver metastasis of breast cancer. In: Journal of Visualized Experiments. 2016 ; Vol. 2016, No. 118. pp. 1-10.
@article{08b8f10ca1084ccdb91189700f9b3619,
title = "A portal vein injection model to study liver metastasis of breast cancer",
abstract = "Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30{\%} of cases with breast cancer metastasis, and results in poor outcomes with median survival rates of only 4.8 - 15 months. Current rodent models of breast cancer metastasis, including primary tumor cell xenograft and spontaneous tumor models, rarely metastasize to the liver. Intracardiac and intrasplenic injection models do result in liver metastases, however these models can be confounded by concomitant secondary-site metastasis, or by compromised immunity due to removal of the spleen to avoid tumor growth at the injection site. To address the need for improved liver metastasis models, a murine portal vein injection method that delivers tumor cells firstly and directly to the liver was developed. This model delivers tumor cells to the liver without complications of concurrent metastases in other organs or removal of the spleen. The optimized portal vein protocol employs small injection volumes of 5 - 10 μl, ≥ 32 gauge needles, and hemostatic gauze at the injection site to control for blood loss. The portal vein injection approach in Balb/c female mice using three syngeneic mammary tumor lines of varying metastatic potential was tested; high-metastatic 4T1 cells, moderate-metastatic D2A1 cells, and low-metastatic D2.OR cells. Concentrations of ≤ 10,000 cells/injection results in a latency of ~ 20 - 40 days for development of liver metastases with the higher metastatic 4T1 and D2A1 lines, and > 55 days for the less aggressive D2.OR line. This model represents an important tool to study breast cancer metastasis to the liver, and may be applicable to other cancers that frequently metastasize to the liver including colorectal and pancreatic adenocarcinomas.",
keywords = "Breast cancer, Cancer research, Intraportal injection, Issue 118, Liver metastasis, Mouse model, Portal vein, Survival surgery",
author = "Goddard, {Erica T.} and Jacob Fischer and Pepper Schedin",
year = "2016",
month = "12",
day = "26",
doi = "10.3791/54903",
language = "English (US)",
volume = "2016",
pages = "1--10",
journal = "Journal of visualized experiments : JoVE",
issn = "1940-087X",
publisher = "MYJoVE Corporation",
number = "118",

}

TY - JOUR

T1 - A portal vein injection model to study liver metastasis of breast cancer

AU - Goddard, Erica T.

AU - Fischer, Jacob

AU - Schedin, Pepper

PY - 2016/12/26

Y1 - 2016/12/26

N2 - Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30% of cases with breast cancer metastasis, and results in poor outcomes with median survival rates of only 4.8 - 15 months. Current rodent models of breast cancer metastasis, including primary tumor cell xenograft and spontaneous tumor models, rarely metastasize to the liver. Intracardiac and intrasplenic injection models do result in liver metastases, however these models can be confounded by concomitant secondary-site metastasis, or by compromised immunity due to removal of the spleen to avoid tumor growth at the injection site. To address the need for improved liver metastasis models, a murine portal vein injection method that delivers tumor cells firstly and directly to the liver was developed. This model delivers tumor cells to the liver without complications of concurrent metastases in other organs or removal of the spleen. The optimized portal vein protocol employs small injection volumes of 5 - 10 μl, ≥ 32 gauge needles, and hemostatic gauze at the injection site to control for blood loss. The portal vein injection approach in Balb/c female mice using three syngeneic mammary tumor lines of varying metastatic potential was tested; high-metastatic 4T1 cells, moderate-metastatic D2A1 cells, and low-metastatic D2.OR cells. Concentrations of ≤ 10,000 cells/injection results in a latency of ~ 20 - 40 days for development of liver metastases with the higher metastatic 4T1 and D2A1 lines, and > 55 days for the less aggressive D2.OR line. This model represents an important tool to study breast cancer metastasis to the liver, and may be applicable to other cancers that frequently metastasize to the liver including colorectal and pancreatic adenocarcinomas.

AB - Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30% of cases with breast cancer metastasis, and results in poor outcomes with median survival rates of only 4.8 - 15 months. Current rodent models of breast cancer metastasis, including primary tumor cell xenograft and spontaneous tumor models, rarely metastasize to the liver. Intracardiac and intrasplenic injection models do result in liver metastases, however these models can be confounded by concomitant secondary-site metastasis, or by compromised immunity due to removal of the spleen to avoid tumor growth at the injection site. To address the need for improved liver metastasis models, a murine portal vein injection method that delivers tumor cells firstly and directly to the liver was developed. This model delivers tumor cells to the liver without complications of concurrent metastases in other organs or removal of the spleen. The optimized portal vein protocol employs small injection volumes of 5 - 10 μl, ≥ 32 gauge needles, and hemostatic gauze at the injection site to control for blood loss. The portal vein injection approach in Balb/c female mice using three syngeneic mammary tumor lines of varying metastatic potential was tested; high-metastatic 4T1 cells, moderate-metastatic D2A1 cells, and low-metastatic D2.OR cells. Concentrations of ≤ 10,000 cells/injection results in a latency of ~ 20 - 40 days for development of liver metastases with the higher metastatic 4T1 and D2A1 lines, and > 55 days for the less aggressive D2.OR line. This model represents an important tool to study breast cancer metastasis to the liver, and may be applicable to other cancers that frequently metastasize to the liver including colorectal and pancreatic adenocarcinomas.

KW - Breast cancer

KW - Cancer research

KW - Intraportal injection

KW - Issue 118

KW - Liver metastasis

KW - Mouse model

KW - Portal vein

KW - Survival surgery

UR - http://www.scopus.com/inward/record.url?scp=85008631602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008631602&partnerID=8YFLogxK

U2 - 10.3791/54903

DO - 10.3791/54903

M3 - Article

VL - 2016

SP - 1

EP - 10

JO - Journal of visualized experiments : JoVE

JF - Journal of visualized experiments : JoVE

SN - 1940-087X

IS - 118

M1 - e54903

ER -